Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to extend the Pre-Crest-X study to further assess the
long-term safety and tolerability of up to 30 grams daily creatine in individuals at-risk for
Huntington's Disease (HD) and to assess whether biomarkers responsive to creatine in
symptomatic individuals are informative in premanifest individuals over a longer duration.